Management of thrombocytopenia due to liver cirrhosis: A review

Table 1 Thrombopoietin-receptor agonists for the treatment of thrombocytopenia

Agent	Target disease	Dose (route)
Recombinant human thrombopoietin
rhTPO	Withdrawn from clinical use	(intravenous)
PEG-rHuMGDF	Withdrawn from clinical use	(subcutaneous)
rhIL-11	Chemotherapy-induced TCP[40,42]	50 μg/kg per day (subcutaneous)
	TCP in patients with cirrhosis[43]	50 μg/kg per day (subcutaneous)
TPO mimetrics (peptide TPO receptor agonists and nonpeptide TPO receptor agonists)
Romiplostim	ITP[47-50]	0.2-10 μg/kg once a week (subcutaneous)
	Myelodysplastic syndrome[51-53]	Once a week (subcutaneous)
	HCV-related TCP[54,97]	2 μg/kg once a week (subcutaneous)
Eltrombopag	ITP[55,56]	50 mg once daily (oral)
	HCV-related TCP	25 mg once daily (oral)
E5501	HCV-related TCP (phase II; NCT00914927)

TPO: Thrombopoietin; PEG-rHuMGDF: Pegylated recombinant human megakaryocyte growth and development factor; rhIL-11: Recombinant human interleukin-11; TCP: Thrombocytopenia; ITP: Immune thrombocytopenic purpura; HCV: Hepatitis C virus.